Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Therapy (Monoclonal Antibodies)
"Measurement of Whole Body Interleukin-6 (IL-6) Production: Prediction of the Efficacy of anti-IL-6 Treatments."
November 20th, 1995
According to the authors' abstract of an article published in Blood, "A major limitation on the therapeutic use of cytokine antagonists is that the amount of cytokine to be neutralized in vivo is not presently known. We previously reported that antiinterleukin-6 (IL-6) monoclonal antibody (MoAb) administered to a patient with multiple myeloma (MM) induced high amounts of IL-6 to circulate in the form of monomeric immune complexes. Based on this observation, the present study developed a new methodology to estimate daily IL-6 production in 13 patients with MM or renal cancer who received anti-IL-6 MoAb. Treatment was considered effective when the production of C-reactive protein (CRP)...
Source: Cancer Weekly (1995-11-20)
|
|
Advertisement |
|
|
